8S-hydroxy-9E,11Z,14Z-eicosatrienoic acid | 889573-69-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 8S-hydroxy-9E,11Z,14Z-eicosatrienoic acid
• 英文别名: (8S,9E,11Z,14Z)-8-hydroxyicosa-9,11,14-trienoic acid
• CAS: 889573-69-7
• 化学式: C₂₀H₃₄O₃
• 分子量: 322.5
• InChiKey: SKIQVURLERJJCK-RDCCVJQZSA-N

物化性质

• 沸点：
  459.0±45.0 °C(Predicted)
• 密度：
  0.971±0.06 g/cm3(Predicted)
• 溶解度：
  0.1 M Na2CO3：2 mg/mL； DMF：可混溶； DMSO：可混溶；乙醇：可混溶； PBS pH 7.2：0.8 mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  23
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Method of neutralising organoboronates with acids
  申请人：Russell Patric Vincent

  公开号：US20060172978A1

  公开（公告）日：2006-08-03

  The use of specified compounds for the manufacture of a medicament for therapeutically neutralising an organoboronate drug. The specified compounds are typically hydroxy fatty acids or hydroperoxy fatty acids, for example 9(S)-HODE, 8(S)-HETRE or 8(S)-HEPE, or their salts or prodrugs. The organoboronate drug may be TRI 50c or a salt or prodrug thereof. Also disclosed are intravenous formulations containing the specified compounds.
• METHOD OF NEUTRALISING ORGANOBORONATES WITH ACIDS
  申请人：Russel Vincent Patric

  公开号：US20100022646A1

  公开（公告）日：2010-01-28

  The use of specified compounds for the manufacture of a medicament for therapeutically neutralising an organoboronate drug. The specified compounds are typically hydroxy fatty acids or hydroperoxy fatty acids, for example 9(S)-HODE, 8(S)-HETRE or 8(S)-HEPE, or their salts or prodrugs. The organoboronate drug may be TRI 50c or a salt or prodrug thereof. Also disclosed are intravenous formulations containing the specified compounds.
• [EN] NEUTRALISING AGENTS FOR BORONIC ACID DRUGS<br/>[FR] AGENTS NEUTRALISANTS POUR MÉDICAMENTS DE TYPE ACIDES BORONIQUES
  申请人：TRIGEN LTD

  公开号：WO2006059083A1

  公开（公告）日：2006-06-08

  [EN] The use of specified compounds for the manufacture of a medicament for therapeutically neutralising an organoboronate drug. The specified compounds are typically hydroxy fatty acids or hydroperoxy fatty acids, for example 9(S)-HODE, 8(S)-HETRE or 8(S)-HEPE, or their salts or prodrugs. The organoboronate drug may be TRI 50c or a salt or prodrug thereof. Also disclosed are intravenous formulations containing the specified compounds.
  [FR] La présente invention décrit l'emploi de composés précis pour la fabrication d'un médicament employé dans la neutralisation thérapeutique d'un médicament de type organoboronate. Les composés spécifiés sont typiquement des acides gras hydroxylés ou des acides gras hydroperoxydes, par exemple 9(S)-HODE, 8(S)-HETRE ou 8(S)-HEPE, leurs sels ou leurs prodrogues. Le médicament de type organoboronate peut être le TRI 50c ou un sel ou une prodrogue de cette substance. La présente invention décrit également des formules pour administration intraveineuse contenant lesdits composés.